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Opioids are some of the most efficacious analgesics used 
in humans. Prolonged administration of opioids, however, 
often causes the development of drug tolerance, thus lim- 
iting their effectiveness. To explore the molecular basis of 
those mechanisms that may contribute to opioid tolerance, 
we have isolated a cDNA for the human P opioid receptor, 
the target of such opioid narcotics as morphine, codeine, 
methadone, and fentanyl. The receptor encoded by this 
cDNA is 400 amino acids long with 94% sequence similarity 
to the rat (r. opioid receptor. Transient expression of this 
cDNA in COS-7 cells produced high-affinity binding sites 
to P-selective agonists and antagonists. This receptor dis- 
plays functional coupling to a recently cloned G-protein- 
activated K+ channel. When both proteins were expressed 
in Xenopus oocytes, functional desensitization developed 
upon repeated stimulation of the P opioid receptor, as ob- 
served by a reduction in K+ current induced by the second 
P receptor activation relative to that induced by the first. 
The extent of desensitization was potentiated by both the 
multifunctional calcium/calmodulin-dependent protein ki- 
nase and protein kinase C. These results demonstrate that 
kinase modulation is a molecular mechanism by which the 
desensitization of P receptor signaling may be regulated at 
the cellular level, suggesting that this cellular mechanism 
may contribute to opioid tolerance in humans. 
[Key words: opioid receptor, desensitization, G-protein- 
activated channel, inward rectifier, protein kinase C, calci- 
umlcalmodulin-dependent protein kinase, Xenopus oo- 
cvtesl 
Opioid peptides and alkaloids affect a number of physiological 
functions including hormone secretion, neurotransmitter release, 
feeding, gastrointestinal motility, and respiratory activity (Pas- 
ternak, 1988). Extensive physiological, behavioral, and phar- 
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macological studies have defined three major types of opioid 
receptors designated 6, K, and p (Wood and Iyengar, 1988; Cor- 
bett et al., 1993). Although there is substantial overlap in their 
tissue distribution and their pharmacological profiles, each 
opioid receptor type maintains a unique pattern of expression 
while displaying characteristic binding affinities for various se- 
lective ligands. The 6 receptors that bind the enkephalin peptides 
are expressed most predominantly in the basal ganglia, striatum, 
and cerebra1 cortex (Mansour et al., 1988; Wood, 1988). Al- 
though 6 receptors have been implicated in spinal analgesia 
(Yaksh, 1981; Porreca et al., 1984), recently it has been sug- 
gested that specific 6 receptor subtypes may also be involved in 
supraspinal analgesia (Pastemak, 1993). The K receptors are 
most highly expressed in cortex, striatum, and hypothalamus 
(Mansour et al., 1987), with various subtypes identified by au- 
toradiography using selective ligands (Neck et al., 1988; Unter- 
wald et al., 1991). With the development of highly selective 
ligands, these receptors have been shown to mediate both spinal 
and supraspinal analgesia (Pasternak, 1993). 
The third major class of opioid binding sites is represented 
by the p opioid receptor. It functions as the physiological target 
of such potent analgesics as morphine and fentanyl, as well as 
the class of endogenous opioid peptides comprised of B-endor- 
phin, enkephalins, and dynorphins. The p. opioid receptor has 
also been implicated in analgesia (Wood and Iyengar, 1988). 
Opioid drugs with high abuse liability such as morphine and 
fentanyl, all bind selectively to the p, opioid receptor. In addition, 
heroin (diacetylmorphine), a semisynthetic derivative of mor- 
phine, crosses the blood-brain barrier more easily due to its 
increased hydrophobicity. Once in the brain, heroin is rapidly 
hydrolyzed to morphine, which acts at the p opioid receptor and 
results in an euphoric effect, thus conferring the reinforcing 
properties of the drug and contributing to the development of 
addiction. Because of the high affinity of these opioid narcotics 
at the p receptor, it is considered the main cellular mediator in 
the development of tolerance (Loh et al., 1988) and opioid ad- 
diction (Di Chiara and North, 1992). 
The activation of all three opioid receptor types can inhibit 
adenylyl cyclase and modulate membrane conductances of Ca*+ 
and K+ (Childers, 1993; North, 1993). The increase in K+ con- 
ductance and the decrease in Ca2+ conductance both serve to 
reduce membrane excitability and may account for the analgesic 
properties of the opioids (North, 1993). Electrophysiological re- 
cordings from neurons located in the locus coeruleus (Williams 
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et al., 1988) and hippocampus (Wimpey and Chavkin, 1991) 
indicate that p opioid receptor stimulation causes membrane hy- 
perpolarization via an inwardly rectifying K+ conductance. The 
effect of the receptors upon the ion channels requires GTP but 
no diffusible cytosolic molecules. The inhibition of adenylyl cy- 
clase, however, implicates a more complex mode involving 
opioid regulation of cellular mechanisms, which includes con- 
trolling the levels of gene expression as well as modulating the 
activity of cellular phosphatases and kinases (Di Chiara and 
North, 1992; Guitart and Nestler, 1993). 
Analgesia and the development of opioid tolerance, depen- 
dence, and addiction have been the subject of extensive studies 
(Collin and Cesselin, 1991). Several schemes, including recep- 
tor-mediated modulation of membrane conductance, have been 
proposed for the acute and chronic actions of opioids in the CNS 
(Johnson and Fleming, 1989). One scheme involves protein 
phosphorylation by various kinases as a means to regulate 
opioid-induced cellular processes. The molecular mechanism of 
such regulation, however, has not been clearly delineated. In the 
study reported here, we expressed the human k opioid receptor 
and a G-protein-activated K+ channel in Xenopus oocytes, and 
examined the role of protein kinases in modulating the p, recep- 
tor-K+ channel coupling and in functional desensitization. 
Materials and Methods 
Isolation of the human k opioid receptor cDNA. The open reading 
frame-containing fragment of the rat p. opioid receptor cDNA was used 
to screen a Xgtl 1 human cDNA library prepared from caudate nucleus 
mRNA (Clontech) under conditions of low stringency [6X SSPE (1.08 
M NaCl, 60 mM NaH,PO,, 6 mM EDTA, pH 7.4), 5X Denhardt’s so- 
lution (0.1% each of Ficoll 400, polyvin$pyrrolidone, bovine serum 
albumin), 0.5% SDS. 100 &ml denatured salmon suerm DNA. at 
48”C]. The final wash was p&Formed in 1 X standard Sal&e citrate (i50 
mM NaCl, 15 mM sodium citrate) 0.1% SDS, at 50°C. Positive A clones 
were plaque purified and subcloned into pBluescript KS(+). Sequencing 
of subclones identified potential opioid-like cDNAs. One was chosen 
for complete sequence determination of both strands. Potential post- 
translational modification sites were identified by using the PCGENE 
analysis program. Alignment of receptor sequences was performed with 
the PILEUP program from the Genetics Computer Group software pack- 
age (Devereux et al., 1984). 
RNA blot analysis. A blot from Clontech, containing 2 Fg of poly- 
adenylated RNA in each lane was used. The RNAs were prepared from 
various brain regions, dissected, and pooled from normal sources, aged 
16 to 75 years old, both male and female, having suffered sudden death 
but having sustained no injuries to the head. The blot was prehybridized, 
hybridized, and washed according to the manufacturer’s specifications. 
Briefly, the blot was prehybridized for 6 hr at 42°C in a solution con- 
taining 5X SSPE, 10X Denhardt’s solution, 100 kg/ml denatured, 
sheared salmon sperm DNA, 50% formamide, and 2% SDS. The cDNA 
probe (25 ng) was labeled using random hexamer priming (Pharmacia). 
Hybridization was performed for 18 hr at 42°C with the addition of 
probe to a density of 2 X lo6 cpm/ml of prehybridization solution. Final 
wash conditions were 0.1 X standard saline citrate and 0.1% SDS at 
50°C for 40 min. The blot was exposed to Kodak XAR film for auto- 
radiography. 
Receptor expression in COS-7 cells. The cDNA containing the open 
reading frame of the receptor was cloned downstream of the human 
cytomegalovirus promoter in the mammalian expression vector, 
pcDNA3 (Invitrogen). COS-7 cells were grown in Dulbecco’s modified 
Eagle’s medium (Sigma D-5648) supplemented with 10% fetal bovine 
serum and 2 mM L- glutamine, and were electroporated with supercoiled 
DNA in 0.4 cm cuvettes at 250 V, using 3 X lo6 cells in a total volume 
of 0.5 ml containing growth medium, 40 pg of expression plasmid, and 
200 kg of sheared salmon sperm DNA. Cells were harvested 48-72 hr 
after electroporation. Cells were harvested by scraping into phosphate- 
buffered saline, pH 7.2, and centrifuged. Cell pellets were resuspended 
in ice-cold lysis buffer (20 mu Tris-HCl, pH 7.4, 5 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride) and lysed with a Dounce homogenizer. 
The homogenate was saved. The pellet was resuspended in lysis buffer 
and centrifuged as described before. Supernatants were combined and 
centrifuged for 10 min at 35.000 X .e. Membrane nellets were washed 
in 50 n& Tris-HCl, pH 7.4, centrifuied again, ani resuspended in 50 
IILM Tris-HCl, pH 7.4. Protein concentrations were determined by the 
method of Bradford (Bradford, 1976). 
Binding analysis. Binding assays were performed essentially as de- 
scribed (Chen et al., 1993a). Binding mixtures containing at least 10 
pg membrane protein were incubated at room temperature for 90 min 
in 50 mu Tris-HCl, pH 7.4 containing 0.2% bovine serum albumin, 
various concentrations of unlabeled lig&ds, and 3H-diprenorphine (3H: 
DPN) or 3H-I~-Ala2.N-MePhe4.G1v-o151-enkeohalin c3H-DAMGO). in a 
final ‘volume‘of 206 ~1. Reactions weie terkinated‘by quickly adding 
3 ml of ice-cold binding buffer (50 mu Tris-HCl, pH 7.4) followed by 
vacuum filtration onto Whatman GF/B glass fiber filters, presoaked for 
3 hr in 0.2% polyethylenimine to minimize nonspecific binding. Filters 
were washed two times each with 3 ml of ice-cold binding buffer before 
placed in vials containing 10 ml liquid scintillation cocktail (CytoScint). 
Radioactivity was determined using a Beckman LS-5801 scintillation 
counter. Nonspecific binding was defined as the radioactivity bound in 
the presence of 10 FM unlabeled naloxone. Saturation analyses were 
performed as above with increasing concentrations of 3H-DPN (0.01 to 
2.5 nM) or )H-DAMGO (0.05 to 5 nM). 
Data for all saturation binding experiments were analyzed by using 
the linear/nonlinear regression analysis program EBDA/LIGAND (Munson, 
1983) to obtain estimates of equilibrium dissociation constant (K,,), Hill 
slope (n,), and binding site density (B,,,) values. Competition-curves 
were obtained with 1.3 nM ?H-DAMGO incubated with concentrations 
of the indicated competitors from 0.01 nM to 5 FM. XC,, values were 
determined through nonlinear regression using InPlot, which utilizes the 
Cheng-Pmsoff equation to determine the K, values (Cheng and Prusoff, 
1973). 
Oocyte expression of the receptor and the G-protein-activated K+ 
channel. The cloning of the G-protein-activated inwardly rectifying K+ 
channel has been described (Dascal et al., 1993; Kubo et al., 1993). 
Synthetic mRNAs for the human p. opioid receptor and the G-protein- 
activated K+ channel were transcribed in vitro, as described (Chen and 
Yu, 1994). RNA yield was calculated from incorporation of the radio- 
active precursor, c@P-UTF? 
Oocytes were isolated using standard methods (Gurdon and Wickens, 
1983). Ovarian lobes were surgically removed from mature Xenopus 
laevis females, and individual oocytes were isolated by digestion with 
2 mglml collagenase in OR-2 [82.5 mu NaCl, 2 mM KCl, 1 IILM MgCl,, 
N-[2-hydroxyethyl]piperazine-Nf-[2-ethanesulfonic . 
:HEP%y), pH 7.51 for l-2 hr at room temperature. Stage V an?$ 
oocytes were injected with a total of 50 nl containing 0.1 ng of each 
mRNA and incubated for 2-3 d at 20°C in ND96 (96 mM NaCl, 2 mu 
KCl, 1 mM MgCl, and 1.5 mM CaCl,) supplemented with 10 kg/ml 
gentamycin and 5% fetal bovine serum. 
Electrophysiology. Oocytes were voltage clamped using a two-mi- 
croelectrode voltage clamp, and the data were analyzed with PCLAMP 
software (Axon Instruments). The electrodes were filled with 3 M KC1 
and had tip resistances of 0.5-10 Ma Oocytes were superfused with 
either a high K+ solution, HK (96 mM KCl, 2 mM NaCl, 1 mM MgCl,, 
and 1.5 mu CaCl,) or ND96 containing the appropriate agonist or ki- 
nase modulator. Phorbol 12-myristate 13-acetate (PMA), a protein 
kinase C (PKC) activator, and 4c+phorbol, an inactive phorbol ester, 
were diluted to final concentrations of 100 nM in ND96 for oocyte 
superfusion. Type II multifunctional calcium/calmodulin-dependent pro- 
tein kinase (CaM kinase II) was purified from rat brain as described 
(Schulman, 1984). The holoenzyme was activated to become 
Caz+/calmodulin-independent by autophosphorylation as described 
(Waldmann et al., 1990) with the following modifications: CaM kinase 
II (75 nM) was incubated with 1 PM calmodulin, 100 PM adenosine 5’- 
0-thiotriphosphate (ATP+), 0.1 mM CaCl,, 2 mu dithiothreitol 
(DTT), 40 mu HEPES, pH 7.4 at 4°C for 20 min. EGTA was added to 
a final concentration of 0.12 mM. Aliquots of autophosphorylated CaM 
kinase II were stored at -70°C until used. Oocytes were injected with 
50 nl of the reaction mixture (2 fmol of CaM kinase II per cell). De- 
sensitization was defined as a decrease in the response of the oocyte to 
a second application of agonist and was quantitatively determined for 
each oocyte as the ratio of the K+ current induced by the second stim- 
ulation relative to that induced by the first. In all current traces, the 
initial inward current is due to switching the superfusate from ND96 (2 
mu KCl) to HK (96 mu KCl). Analysis of variance and Student’s t test 
were used to compare the treatment groups. 
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Figure I. Sequence comparison of the human and rat opioid receptors 
and expression of the human p. opioid receptor in human brain. Seven 
putative transmembrane domains are underlined and numbered TM1 
through TM7. Amino acids identical to those in the human u opioid 
receptor are depicted as hyphens (-). Gaps are shown by periods (.). 
Putative N-linked glycosylation sites ($); potential site for phosphory- 
lation by multifunctional Ca2+/calmodulin-dependent pro ein kinase 
(CaM kinase II) (5); conserved aspartic acid residues proposed to in- 
teract with the amine group of ligands (+ ); conserved cysteine residues 
that may form a disulfide bond (=); potential sites for phosphorylation 
by protein kinase C (PKC) (0); putative phosphorylation site for PKC 
or CaM kinase II (V); potential phosphorylation site for CaM kinase II 
or CAMP-dependenikinase A (?); potential palmitoylation site (J). The 
cDNA sequence has been submitted to GenBank (accession umber 
L29301). 
Results 
Isolation and characterization of cDNA encoding the human F 
opioid receptor 
To clone the human p opioid receptor, a cDNA library con- 
structed from human caudate nucleus mRNA was screened un- 
der reduced stringency with the rat p opioid receptor cDNA 
(Chen et al., 1993a), and the cDNA inserts from positive clones 
were subcloned into pBluescript. Complete sequence analysis of 
one cDNA revealed an open reading frame of 1200 base pairs 
(bp), predicting a protein of 400 amino acids. Hydropathy anal- 
ysis of the deduced protein indicated the presence of seven hy- 
drophobic domains, typical of G-protein<oupled receptors (Col- 
lins et al., 1991). The sequence of this protein displays 94% 
similarity to the rat p opioid receptor (Chen et al., 1993a; Wang 
et al., 1993; Fukuda et al., 1993; Thompson et al., 1993), sug- 
gesting that it is the human homolog of the p opioid receptor. 
It also displays 62% and 58% similarities to the murine 6 (Kief- 
fer et al., 1993; Evans et al., 1993; Fukuda et al., 1993) and K 
(Chen et al., 1993b; Li et al., 1993; Meng et al., 1993; Minami 
et al., 1993; Yasuda et al., 1993) opioid receptors, respectively. 
Figure 1 displays the alignment of the human p opioid receptor 
sequence against the rat p., K, and 6 opioid receptor sequences. 
The regions of greatest divergence among the different types 
of opioid receptors include the N- and C-termini, the fourth and 
sixth transmembrane domains, and the second and third extra- 
cellular loops. Several potential sites for posttranslational mod- 
ification are present (Fig. 1). The N-terminus contains five po- 
tential N-linked glycosylation sites that remain conserved be- 
tween the human and rat p opioid receptors. Aspartic acid res- 
idues that occur in other G-protein-coupled receptors and have 
been shown to interact with the protonated amine group of var- 
ious ligands (Dohlmann et al., 1991) are also present in the 
putative transmembrane domains TM2 and TM3 of the p recep- 
tor, and two conserved cysteine residues believed to be involved 
in disulfide bonding (Dixon et al., 1988) occur in the first and 
second extracellular loops. There are also potential phosphory- 
lation sites for CAMP-dependent protein kinase (PKA) and PKC, 
as well as CaM kinase. One of these sites, conserved among all 
opioid receptor types, occurs in the third intracellular loop. This 
region between TM5 and TM6 is often referred to as the G-pro- 
tein loop because of its importance in G-protein coupling (Dohl- 
mann et al., 1991). The conservation of this site suggests that 
phosphorylation may play a role in modulating signal transduc- 
tion of all the opioid receptors. There is also a cysteine residue 
in the C-terminus that is conserved among many G-protein- 
coupled receptors and that may serve as a target for palmitoyl- 
ation (Collins et al., 1991). 
Expression of the receptor mRNA in human brain 
To estimate the relative abundance of the p opioid receptor 
mRNA, a blot containing polyadenylated RNA from various 
regions of the human brain was hybridized with a probe con- 
taining the open reading frame of the human p. opioid receptor 
cDNA (Fig. 2). The predominant mRNA is approximately 14 
kilobases (kb), similar in size to those reported for the rat p. 
opioid receptor (Fukuda et al., 1993; Thompson et al., 1993; 
Delfs et al., 1994). This message is abundant in the thalamus, 
hypothalamus, and subthalamic nucleus where p. opioid recep- 
tors are believed to modulate nociception. Somewhat lower lev- 
els of message are observed in the caudate nucleus and amyg- 
dala, which harbor synapses between cortical neurons and motor 
nuclei located in the brainstem and spinal cord. These basal 
ganglia as well as the subthalamic nucleus that serves as a “way 
station” for this extrapyramidal tract may allow for opioid-me- 
diated integration of somatosensory input and motor output. The 
substantia nigra, corpus callosum, and hippocampus express the 
p receptor mRNA in lower abundance than that seen in the other 
brain subregions. Recent in situ hybridization studies in rat brain 
(Thompson et al., 1993; Delfs et al., 1994) have provided cel- 
lular resolution of p, opioid receptor message expression and 
corroborate our results of the subregion RNA analysis. 
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Pharmacological characterization of the receptor 
The cDNA containing the open reading frame was subcloned 
into a mammalian expression vector containing the human cy- 
tomegalovirus promoter. This construct was transiently ex- 
pressed in COS-7 cells, and saturation binding of 3H-diprenor- 
phine to the membranes was performed. As shown in Figure 3A, 
a saturable binding was observed with a Kd of 0.23 _+ 0.01 nM 
(n = 3) and a B,, of 549 rt 26 fmol/mg of membrane protein. 
Hill coefficients (0.97 & 0.01) did not suggest the presence of 
any cooperative binding effects. The equilibrium binding param- 
eters for 3H-DAMG0, a p-selective agonist, were 1.6 & 0.15 
nM for the Kd and 381 & 25 fmol/mg membrane protein for 
Lx. 
- 
9.5 - 
7.5 - 
4.4 - 
2.4 - 
To characterize the pharmacological profile of this receptor, 
competitive displacement experiments were performed with var- 
ious opioid ligands. Representative binding isotherms are shown 
in Figure 3B, and IC,, and K, values are summarized in Table 
1. The p-selective agonist, DAMGO, displaced 3H-DAMG0 
binding with high affinity (K, = 0.9 nM). Two other opioid li- 
gands, [D-Per+]enkephalin (DPDPE) and U-50,488, which are 
selective for 6 and K receptors, respectively, displayed low-af- 
finity binding with K, values above the p,M range. Displacement 
of ?H-DAMGO from membranes expressing the human p. opioid 
receptor was also performed using opioid antagonists. Cypro- 
dime and naloxonazine, both p-selective antagonists, bound with 
K, values in the IIM range. Naloxone, a nonselective opioid an- 
tagonist, bound with an affinity nearly equal to that of DAMGO. 
The rank order affinity for these ligands (Table 1) and the high 
affinity for p-selective ligands indicate that this cDNA encodes 
a p. opioid receptor. 
IA - 
Figure 2. RNA blot analysis of the p, opioid receptor message in 
various regions of the human brain. The size markers are indicated on 
the left. The predominant 14 kb band is marked by an arrow. 
produced by exposure to DAMGO was completely blocked by 
the opioid antagonist naloxone (Fig. 4B). The current-voltage 
relationship of this K+ channel was characteristic of an inward 
rectifier. With progressive hyperpolarization, the magnitude of 
current increased (Fig. 4C). However, as the membrane was de- 
polarized, current flow decreased until there was little to none 
at a membrane potential of 0 mV. Thus, the human p. opioid 
receptor is capable of coupling to the G-protein-activated K+ 
channel. 
Competitive displacement binding was also done with several 
therapeutic opioid ligands. Morphine, methadone, and fentanyl, 
archetypal drugs that bind the p opioid receptor, all displayed 
nM affinity. Codeine showed lower affinity with K, values in the 
high nM range. Several endogenous opioid peptides were also 
tested. Met-enkephalin, Leu-enkephalin, and B-endorphin all 
displayed high affinities comparable to that observed for 
DAMGO, suggesting that they may act at this receptor in vivo. 
Functional coupling to a G-protein-activated K* channel 
Activation of opioid receptors has been known to affect mem- 
brane permeability to potassium (North, 1993). Stimulation of 
the p. opioid receptor hyperpolarizes cellular membranes by in- 
creasing the K+ conductance through an inwardly rectifying 
channel (North et al., 1987; Wimpey and Chavkin, 1991). The 
recent cloning of an inwardly rectifying K+ channel (Dascal et 
al., 1993; Kubo et al., 1993) had shown that it is expressed in 
the brain. We were interested in testing whether the human p. 
opioid receptor coupled to this G-protein-activated K+ channel. 
Messenger RNAs encoding both proteins were generated by in 
vitro transcription and injected into Xenopus oocytes. Coupling 
of the receptor to the K+ channel was assessed by two-electrode 
voltage clamp. When the receptor was activated by superfusing 
the oocytes with DAMGO, an inward current was observed (Fig. 
4A). This was a K+ current through the inwardly rectifying K+ 
channel, since the current varied in amplitude with the concen- 
tration of K+ in the extracellular solution and was blocked by 
the K+ channel blocker Ba*+ (100 FM). Oocytes injected with 
the receptor mRNA alone did not produce the current upon 
DAMGO stimulation (data not shown). This K+ current was 
induced by activation of the p. opioid receptor, since the current 
Repeated agonist stimulation desensitizes receptor-channel 
coupling 
Prolonged exposure to opioids are known to produce tolerance 
(Di Chiara and North, 1992). At the cellular level, tolerance is 
manifested as a diminished response to opioids (Johnson and 
Fleming, 1989). Since the opioid narcotics with abuse liability, 
such as morphine and fentanyl, display high affinity at the p 
opioid receptor (Table l), we were interested in examining 
whether the intracellular signaling by the iv, opioid receptor dis- 
plays desensitization. Using the receptor-K+ channel coupling 
as an assay, oocytes were subjected to repeated agonist stimu- 
lation to determine whether functional desensitization of the p. 
receptor-K+ channel coupling occurs. For this purpose, a pro- 
tocol of repeated agonist application was used (Fig. 5A, top), 
and “desensitization” was operationally defined as a reduction 
in the responsiveness of the cell. Due to the variation in mRNA 
expression among different cells, the amplitude of the K+ cur- 
rents vary from oocyte to oocyte. Therefore, desensitization was 
quantitatively described as a ratio of two DAMGO-induced K+ 
currents in the same oocyte. Current traces at -80 mV were 
recorded for each stimulation with DAMGO to evaluate the ex- 
tent of desensitization. In addition, currents over the entire volt- 
age range between - 160 mV and +40 mV were recorded using 
either ramped (Fig. 5A, middle) or stepped voltage commands 
(Fig. 5A, bottom). Repeated stimulation of the p receptor re- 
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Figure 3. Saturation and displace- 
ment binding of labeled ligands using 
cell membranes transiently expressing 
the human p opioid receptor. A, Satu- 
ration binding of ‘H-diprenorphine 
(DPN) was determined using mem- 
branes prepared from cDNA-transfect- 
ed COS-7 cells. Data for all saturation 
binding experiments were analyzed us- 
ing the linear/nonlinear regression 
analysis program EBDA/LIGAND (Mun- 
son, 1983) to obtain estimates of Kd 
and B,,, values. Data represent mean 
+ standard error mean (SEM) of three 
separate experiments performed in du- 
plicate. Inset: Saturation binding plot- 
ted in Scatchard coordinates (represen- 
tative curve shown). B, Displacement 
of 3H-DAMG0 binding with unlabeled 
ligands as competitors. Displacement 
of 3H-DAMG0 binding was performed 
using 1.3 nM 3H-DAMG0 and unla- 
beled competitors with concentrations 
ranging from 0.01 nM to 5 FM. Data 
represent mean k SEM of three sepa- 
rate experiments performed in dupli- 
cate. 
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sulted in a moderate and consistent desensitization, as observed 
by a reduction in the second response. The second response was 
reduced to 83% -t 8% (n = 4) relative to the first (Fig. 7), and 
subsequent stimulation of the oocyte with DAMGO did not re- 
sult in any further decrease in the inward current (data not 
shown). 
Protein kinases potentiate desensitization of receptor-channel 
coupling 
Previous studies had shown that activation of PKC was capable 
of attenuating opioid receptor activity in neuroblastoma cells 
(Louie et al., 1990) as well as affecting ionic conductances using 
acutely dissociated neurons in culture (Doerner et al., 1988). We 
were interested in observing whether stimulation of PKC affects 
the coupling of the human p opioid receptor to the K+ channel. 
Using the protocol described above (Fig. 5A, top), Xenopus oo- 
cytes were superfused for 10-15 min after the initial DAMGO 
stimulation with PMA, a PKC-activating phorbol ester. Oocytes 
were again stimulated with DAMGO. Comparison between the 
peak current responses to DAMGO before and after PMA treat- 
ment reveals the extent of desensitization (Fig. 5B, top). PMA 
reduced the second response to 29% + 7% (n = 4) relative to 
the first (Fig. 7) at the holding potential of -80 mV. Current 
responses were also obtained using a ramped voltage command. 
Representative current traces from before and after PMA treat- 
ment are superimposed (Fig. 5B, middle). Currents produced by 
stepped voltage commands were measured and the reduction in 
response was shown to be proportionally uniform across the 
voltage range (Fig. 5B, bottom). Thus, activation of PKC poten- 
tiated the desensitization of the p, opioid receptor-activated K+ 
current. To control for possible nonspecific effects caused by 
application of a phorbol ester to the cellular membrane, oocytes 
were treated with 4ol-phorbol, a phorbol ester that does not ac- 
tivate PKC (Blumberg et al., 1984). Recordings of peak current 
amplitude showed that the 4a-phorbol did not potentiate desen- 
sitization (87% + 2%, n = 4) beyond that observed with no 
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Table 1. IC,, and K, values of various opioid receptor ligands for 
the cloned human p receptor 
Competitor IC,” ml) K. (nM) 
B-Endorphin 3.4 ? 0.5 1.8 k 0.3 
Leu-enkephalin 17.7 2 7.4 9.5 k 4.0 
Met-enkephalin 4.1 ? 0.1 2.2 k 0.1 
DAMGO 1.7 * 0.4 0.9 + 0.2 
DPDPE >lOOO >lOOO 
U-50, 488 >lOOO >lOOO 
Morphine 6.6 + 0.5 3.6 k 0.3 
Fentanyl 4.8 +- 0.8 2.6 + 0.4 
Methadone 6.9 ? 0.1 3.7 + 0.03 
Codeine 235.3 -r- 14.5 128.0 + 8.7 
Naloxone 1.5 ? 0.2 0.8 k 0.1 
Naloxonazine 1.8 +- .2 1.0 2 0.1 
CHB 25.6 k 9.5 14.1 + 5.3 
Competition curves were obtained with 1.3 nM IH-DAMGO incubated with 
concentrations of the indicated competitors ranging from 0.01 nsr to 5 JIM (200 
(~1 final volume). IC,, values were determined using nonlinear regression. K, 
values were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 
1973). Values shown are mean + SEM of three experiments performed in 
duplicate. CHB, cyprodime HBr; DAMGO, [o-A1al.N.MePhe4,Gly-oP-en- 
kephalin; DPDPE, [o-PerF]enkephalin. 
treatment (Figs. 5C, top; 7). Membrane currents from ramped 
(Fig. 5C, middle) and stepped voltage commands (Fig. 5C, bot- 
tom) before and after 4a-phorbol treatment exhibited moderate 
desensitization comparable to that with no treatment (data not 
shown), demonstrating that the inactive form of the phorbol ester 
did not potentiate desensitization. Therefore, these results indi- 
cate that potentiation of the desensitization by PMA reflects the 
activation of PKC. 
Physiologically, PKC is activated by diacylglycerol (DAG), a 
second messenger of the phosphatidylinositol pathway. This sig- 
naling pathway also generates another second messenger, ino- 
sitol 1,4,5-trisphosphate (IP,), which triggers an increase in in- 
tracellular calcium and results in the activation of CaM kinase 
II (Schulman and Hanson, 1993). We were interested in testing 
whether CaM kinase II could modulate the p, opioid receptor- 
mediated K+ current. Using the protocol described above, oo- 
cytes were injected with the activated form of CaM kinase II 
between the first and second stimulations by DAMGO, and the 
effect on the receptor-induced K+ current was evaluated. Injec- 
tion of activated CaM kinase II reduced the second response to 
44% ? 4% (n = 8) compared to the first (Figs. 6A, top; 7). 
CaM kinase II clearly potentiated the desensitization, causing a 
twofold decrease in the second response relative to uninjected 
oocytes. This reduction in the second response was proportional 
across the entire voltage range (Fig. 6A, middle and bottom). As 
a negative control, the same CaM kinase II solution was placed 
in a boiling water bath for 5 min and chilled on ice before 
injection into the oocytes. Boiled CaM kinase II did not poten- 
tiate desensitization (84% ? 8%, n = 8) beyond that observed 
with uninjected controls (Figs. 6B, top; 7). Currents measured 
during the ramped or stepped voltage commands were similar 
both before and after injection of boiled CaM kinase II (Fig. 6B, 
middle and bottom). We concluded that activated CaM kinase II 
can therefore potentiate the desensitization of the p opioid re- 
ceptor-activated K+ current. 
A 
DAMGO 
- / v -bnA 
1 min 
B 
DAMGO + Naloxone 
Figure 4. Human p, opioid receptor coupling to the G-protein-acti- 
vated K+ channel. Electrophysiological analysis of oocytes injected with 
RNAs encoding the human p. opioid receptor and the G-protein-acti- 
vated K+ channel. Membrane current traces were recorded at a holding 
potential of -80 mV. Oocytes were bathed in a high K+ solution and 
were exposed to either (A) 1 ~.LM DAMGO or (B) 1 pM DAMGO plus 
10 FM naloxone. Inward current is downward. C, The current-voltage 
relationship plotted as an I/V curve. DAMGO-induced membrane cur- 
rents were recorded with voltage steps ranging from -160 mV to 0 
mV. The DAMGO-induced net currents were derived by subtracting the 
currents recorded before DAMGO application from those during DAM- 
GO application. 
Discussion 
The p opioid receptor mediates the effects of such potent an- 
algesics as morphine, codeine, and fentanyl. To explore the mo- 
lecular basis of opioid actions and the possible mechanisms in- 
volved in tolerance development, a cDNA clone encoding the 
human p opioid receptor was isolated. The deduced protein se- 
quence of this receptor is very similar to that of its homolog 
from the rat brain (Chen et al., 1993a). Although the N-terminus 
of the human p. opioid receptor contains two additional amino 
acids not found in the rat homolog, the protein sequences are so 
similar that only two conservative amino acid substitutions occur 
in the region between TM1 and TM7, the core region of G-pro- 
teincoupled receptors that are involved in ligand binding and 
signal transduction. Such structural conservation between the 
human and rat p opioid receptors would imply a functional con- 
servation. Pharmacologically, they display very similar binding 
profiles for p-selective and nonselective ligands. Binding studies 
using brain homogenate have shown that opioid narcotics that 
have high liability of abuse, such as morphine and fentanyl, all 
bind to the p opioid receptor rather selectively (Pasternak, 
1993). Using the murine cDNA clones to express the p,, 6, and 
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Figure 5. Desensitization of the p opioid receptor-K+ channel coupling and the effect of PKC. Membrane currents were recorded in oocytes 
injected with both the human p opioid receptor and the K+ channel mRNAs. A: Top, A schematic diagram of the experimental protocol. The oocyte 
was voltage clamped at -80 mV and superfused with 500 nM DAMGO in HK solution to elicit the K+ current. After the first DAMGO stimulation, 
the superfusate was switched to ND96 containing 1.8 mu CaCl, and the oocyte either received no treatment or was subjected to drug treatment or 
enzyme injection. The superfusate was then switched back to HK solution to record the second DAMGO-induced membrane current. The recorded 
membrane current trace is shown. Please note that changes in the basal current level upon solution change between HK and ND96 reflects a larger 
K+ current in HK due to elevated K+ concentration. A: Middle, The ramped voltage command used to record currents before and during DAMGO 
stimulation. From a holding potential of -80 mV, the membrane voltage was stepped to - 160 mV, and ramped to +40 mV before stepping back 
to the holding potential. Net currents were derived by subtracting the currents before DAMGO application from those during DAMGO application. 
A, Bottom, The step voltage commands used to record currents before and during DAMGO application. The step command ranged from - 160 mV 
to +40 mV, with 20 mV increments. Net currents were derived by subtracting the currents before DAMGO application from those during DAMGO 
application. B, Membrane currents elicited by DAMGO application before and after treatment with 100 nM PMA for 10-15 min. B: Top, Current 
recorded at a holding potential of -80 mV. B: Middle and bottom, Net currents from the first and second DAMGO applications are obtained from 
either ramped (middle) or stepped (bottom) voltage commands. C, Membrane currents recorded during DAMGO application before and after 
treatment with 100 nM 4o-phorbol for lo-15 min. C: Top/middle/bottom, Membrane currents are recorded and displayed as in B. 
K opioid receptors, these opioid narcotics showed highly selec- 
tive binding at the k receptor (Raynor et al., 1994). With the 
human f.~ opioid receptor, we now also observed nM affinities of 
the receptor for these compounds (Table 1). Also, IC,, values 
for DAMGO, naloxone, morphine, and diprenorphine using hu- 
man brain preparations (Pilapil et al., 1987; Pfeiffer et al., 1982) 
are in excellent agreement with those reported here. Since these 
ligands possess both powerful analgesic effects and abuse po- 
tential, the p, opioid receptor may, indeed, be the physiological 
mediator of the nociceptive and addictive properties of these 
narcotics. During the preparation of this manuscript, another hu- 
man p. opioid receptor, designated hpOR1, was reported (Wang 
et al., 1994) that differs from the receptor we cloned by one 
amino acid in the N-terminal region. The binding profiles are 
almost identical. 
A major effect of the p opioid receptor activity in brain is the 
decrease of neuronal membrane excitability. One of the mech- 
anisms for this effect is an increase in K+ conductance, accom- 
plished by the opening of an inward rectifier, resulting in out- 
ward K+ currents and hyperpolarization of the cell membrane 
(North, 1986, 1993; Chavkin, 1988). With the cloning of an 
inwardly rectifying K+ channel that can be activated by a num- 
ber of neurotransmitter receptors (Dascal et al., 1993; Kubo et 
al., 1993), it became possible to examine whether the p. opioid 
receptor could also activate this channel. We have shown that 
the p opioid receptor from both rat (Chen and Yu, 1994) and 
human (Fig. 4) can activate this channel, causing an increase in 
K+ conductance. The receptor-channel coupling is clearly me- 
diated through heterotrimeric G-proteins, since a nonhydrolyz- 
able GTP analog, guanosine 5’-U-(thiotriphosphate) (GTP-yS), 
can enhance the p receptor-activated K’ current while pertussis 
toxin treatment decreases it (Chen and Yu, 1994). Thus, our data 
suggest that the p receptor-channel coupling may be the basis 
for the p, receptor-induced increase in K+ conductance. 
Receptor-mediated signaling processes often display desensi- 
tization, operationally defined as a decrease in the cellular re- 
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sponse to further agonist stimulation upon continuous or re- has been hypothesized that several intermediates within the sig- 
peated exposure to agonist (Benovic et al., 1988). This may nal transduction pathway may serve as targets for this mecha- 
serve as a physiological mechanism to prevent overstimulation nism (Nestler et al., 1993). In the neurons of the rat locus coe- 
of the neuron. The p, opioid receptor is the physiological target ruleus, desensitization was observed as a reduction in membrane 
of morphine and fentanyl, analgesics used in the clinical man- hyperpolarization upon continued application of Met5-enkepha- 
agement of pain. Prolonged use of morphine and related opioids lin. A decrease in K+ conductance was shown to be responsible 
can lead to the development of tolerance, necessitating dosage for the observed effect (Harris and Williams, 1991). In oocytes 
increases to achieve the same degree of its initial physiological expressing the human p, opioid receptor and the inwardly rec- 
effect. At the cellular level, tolerance manifests itself as a de- tifying K+ channel, we used a protocol to evaluate desensitiza- 
sensitized responsiveness to repeated opioid applications, and it tion by measuring the K+ currents evoked by sequential acti- 
! 
No 
treatment 
400 q 
600 5 
Figure 6. Effect of CaM kinase II on 
the coupling between the human p 
opioid receptor and K+ channel. Mem- 
brane currents were recorded in oo- 
cytes injected with both the human p 
opioid receptor and the K+ channel 
mRNAs. Experimental protocol and 
voltage commands are as described in 
Figure 5. A: Toplmiddlelbottom, Mem- 
brane currents recorded during DAM- 
GO application before and after injec- 
tion of activated CaM kinase II. A: Top, 
Current recorded at a holding potential 
of -80 mV. A: Middle and bottom, Net 
currents from the first and second 
DAMGO applications are obtained 
from ramped (middle) or stepped (bot- 
tom) voltage commands. B: Toplmid- 
dlelbottom, Membrane currents record- 
ed during DAMGO application before 
and after injection of boiled CaM ki- 
nase II. Membrane currents are record- 
ed and displayed as in the top, middle 
and bottom panels of A. 
I Figure 7. Desensitization of the hu- 
PMA 4a-phorbol CaMKlI Boiled 
CaMKll 
man p opioid receptor-induced K+ cur- 
rent and modulation by PKC and CaM 
kinase II. Oocytes were injected with 
both the human p opioid receptor and 
the inwardly rectifying K+ channel 
mRNAs. Membrane currents were re- 
corded at a holding potential of -80 
mV during DAMGO anolication and 
recording of peak currenis: Data are ex- 
pressed as the percentage of the peak 
current induced by the second DAM- 
GO stimulation over that of the first 
stimulation and are presented as mean 
2 SEM. Treatment is labeled on the 
bottom of each data group. Analysis of 
variance ana post not test results: -In- 
dicates p < 0.05 as compared to un- 
treated group. 
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Figure 8. Diagram depicting a model 
for crosstalk between different recep- 
tor-coupled signaling pathways. The 
model is based on both the results from 
this study and the evidence reported in 
the literature. The human p opioid re- 
ceptor and another type of surface re- 
ceptor are depicted in the cell mem- 
brane as p and R, respectively. Open 
circles represent receptor ligands. Po- 
tassium channel is shown with ionic ef- 
flux. Abbreviations for intracellular 
proteins: G, guanine nucleotide binding 
protein; PKC, protein kinase C; Cu- 
MKIZ, multifunctional Ca2+/calmodu- 
lin-dependent protein kinase; PDE, 
phosphodiesterase involved in PIP, hy- 
drolysis. Abbreviations for intracellular 
molecules: DAG, diacylglycerol; PIP,, 
phosphatidylinositol 4,Sbisphosphate; 
IP,, inositol 1,4,5-trisphosphate. Ar- 
rows pointing from second-messenger 
molecules to proteins indicate a stim- 
ulatory influence. Arrows with (-) in- 
dicate an inhibitory effect on interac- 
tions. Upward arrow adjacent to Ca++ 
indicates an increase in intracellular 
calcium. 
0 PKC 
Calmodulin A tCa++-IP 3 
vation of the receptor with a p.-selective agonist (Fig. 5A). Com- 
parison of the maximum K+ currents, thus, indicates the extent 
of desensitization between the first stimulus and second stimulus 
caused by activation of the receptor. Using this paradigm, de- 
sensitization occurred consistently, as observed in a reduction of 
the K+ current to -80% of the initial response evoked by re- 
ceptor activation (Fig. 7). Thus, desensitization of receptor-chan- 
nel coupling appears to be a normal process when studied in 
oocytes, suggesting that such a phenomenon may exist as an 
adaptive process in neurons to modulate the responsiveness of 
the p, receptor-mediated increase in K+ conductance. 
Desensitization of receptor-channel coupling may involve sev- 
eral mechanisms at the cellular level. For acute desensitization 
such as that studied here with a time-scale of less than 30 min, 
new protein synthesis or receptor turnover are unlikely to ac- 
count for the majority of the observed effects. Covalent modi- 
fication through kinase-mediated phosphorylation, on the other 
hand, appears to play an essential role. We demonstrated that 
both PKC and CaM kinase II potentiate desensitization (Figs. 5, 
6). Activation of PKC by the phorbol ester PMA and injection 
of the activated type II CaM kinase both resulted in potentiation 
of desensitization (Fig. 7). In contrast, treatment with the inac- 
tive 4a-phorbol ester or injection of boiled CaM kinase II did 
not potentiate desensitization beyond that observed in oocytes 
that had been untreated (Fig. 7) suggesting that the effect of 
potentiation is specific to the active form of these kinases. Our 
observations in Xenopus oocytes are consistent with the reports 
that in rat locus coeruleus neurons containing p. opioid receptors, 
treatment with staurosporine, a nonselective kinase inhibitor that 
can inhibit both PKC (Tamaoki, 1991) and CaM kinase II (Yan- 
agihara et al., 1991), reduced desensitization of p. receptor-me- 
diated hyperpolarization (Harris and Williams, 1991). Processes 
that elevate the activity of these cellular kin&es, therefore, may 
play an important role in regulating the extent of the p receptor- 
K+ channel coupling. 
Both PKC and CaM kinase II are cellular effecters of a G-pro- 
tein-activated phosphodiesterase, phospholipase C (PLC). The 
activation of PLC causes the production of DAG and IP,, two 
intracellular second-messenger molecules that represent a bifur- 
cation in this signal transduction pathway (Berridge, 1987). 
Whereas DAG activates PKC, IP, triggers Ca2+ release from 
intracellular stores. Since CaM kinase II is activated by physi- 
ological elevations in cytosolic Ca*+ levels (MacNicol and 
Schulman, 1992; Schulman and Hanson, 1993), stimulation of 
receptors linked to PLC may cause activation of both PKC and 
CaM kinase. Other neurotransmitter receptors that belong to the 
family of G-protein-coupled receptors influence the steady-state 
levels of CAMP by either stimulating or inhibiting the activity 
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of adenylyl cyclase, as is the case for the P-adrenergic and 
opioid receptors, respectively (Benovic et al., 1988; Childers, 
1993). The widespread distribution of many G-protein-coupled 
receptors suggests that some may be found within similar struc- 
tures of the brain. In fact, in situ hybridization has shown that 
messages encoding receptors that use either similar (Lester et 
al., 1993) or different (Weiner et al., 1990) signaling pathways 
do coexist within the same cell. Thus, crosstalk between differ- 
ent receptor-coupled signaling pathways may serve as a modu- 
latory mechanism to fine tune the function of a neuron. Our 
results provide an example of such crosstalk, demonstrating the 
modulatory effect on p opioid receptor-K+ channel coupling by 
CaM kinase II and PKC, both of which are effecters of the PLC 
signaling pathway. The diagram in Figure 8 depicts a model of 
this crosstalk. In this model, the effect of both CaM kinase II 
and PKC on p. opioid receptor-K+ channel coupling is marked 
with minus signs, highlighting the fact that these kinases poten- 
tiate the desensitization of the p, opioid receptor-mediated K+ 
current. It should be noted that our results only demonstrate the 
modulatory role of these kinases. The pathway from another 
type of membrane receptor through PLC to activate the kinases 
is based on reports in the literature and has not been shown in 
the oocyte expression system that we used. It should also be 
noted that it is not known which protein is the target of these 
kinases, whether the target be the k opioid receptor, the G-pro- 
tein, the K+ channel, or some other intermediary factors. Thus, 
the diagram in Figure 8 only indicates the possibility that signal 
transduction mechanisms may affect one another, when the re- 
ceptors to which they couple are present on the same neuron. 
We have attempted to investigate the role of CaM kinase II 
and PKC in the mechanisms involved in acute desensitization. 
The schematic diagram in Figure 8 depicts the individual effects 
of these kinases on opioid receptor-mediated K+ channel activ- 
ity. Our data demonstrate that an intricate network of modulation 
among receptors, G-protein effectors, and protein kinases can 
function in oocytes with exogenously expressed receptors and 
ion channels as well as endogenous components, providing a 
possible mechanism of functional modulation that may occur in 
neurons to regulate opioid tolerance. With the cloning of the 
human p. opioid receptor, future efforts will focus on identifying 
other key elements involved in this modulatory network. Results 
from such studies will further our understanding of the molec- 
ular mechanisms that underlie the regulation of receptor-medi- 
ated neuronal activity, with particular focus on the cellular basis 
of the initial stages in the development of opioid tolerance. 
References 
Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ (1988) Regulation 
of adenylyl cyclase-coupled P-adrenergic receptors. Annu Rev Cell 
Biol 4:405428. 
Berridge MJ (1987) Inositol trisphosphate and diacylglycerol: two in- 
teracting second messengers. Annu Rev Biochem 56:159-193. 
Blumberg PM, Jaken S, Konig B, Sharkey NA, Leach KL, Jeng AY, 
Yeh E (1984) Mechanism of action of the phorbol ester tumor pro- 
moters: specific receptors for lipophilic ligands. Biochem Pharmacol 
33:933-940. 
Bradford MM (1976) A rapid and sensitive method for the quantitation 
of microgram quantities of protein utilizing the principle of protein- 
dye binding. Anal Biochem 721248-254. 
Chavkin C (1988) Electrophysiology of opiates and opioid peptides. 
In: The opiate receptors (Pastern& GW, ed), pp 273-303. Clifton, 
NJ: Humana. 
Cheng Y, Prusoff W (1973) Relationship between the inhibition con- 
stant (K,) and the concentration of inhibitor which causes 50 percent 
inhibition (IC,,) of an enzymatic reaction. Biochem Pharmacol 22: 
3099-3 108. 
Chen Y, Yu L (1994) Differential regulation by CAMP-dependent pro- 
tein kinase and protein kinase C ofthe p opibid recepto; coupling to 
a G urotein-activated K+ channel. J Biol Chem 269:7839-7842. 
Chen 9, Mestek A, Liu J, Hurley JA, Yu L (1993a) Molecular cloning 
and functional expression of a p-opioid receptor from rat brain. Mol 
Pharmacol 44:8-12. 
Chen Y, Mestek A, Liu J, Yu L (1993b) Molecular cloning of a rat K 
opioid receptor reveals sequence similarities to the w and 6 opioid 
receptors. Biochem J 295:625-628. 
Childers S (1993) Opioid receptor-coupled second messenger systems. 
In: Handbook of experimental pharmacology: opioids I, Vol 104 
(Herz A, ed), pp 189-216. Berlin: Springer. 
Collin E, Cesselin F (1991) Neurobiological mechanisms of opioid 
tolerance and dependence. Clin Neuropharmacol 14:465-488. 
Collins S, Lohse MJ, O’Dowd B, Caron MG, Lefkowitz RJ (1991) 
Structure and regulation of G protein-coupled receptors: the pz-ad- 
renergic receptor as a model. Vitam Horm 46:1-39. 
Corbett A, Paterson S, Kosterlitz H (1993) Selectivity of ligands for 
opioid receptors. In: Handbook of experimental pharmacology: 
opioids I, Vol 104 (Herz A, ed), pp 645-679. Berlin: Springer. 
Dascal N, Lim NF, Schreibmayer W, Wang W, Davidson N, Lester HA 
(1993) Expression of an atria1 G-protein-activated potassium channel 
in Xenopus oocytes. Proc Nat1 Acad Sci USA 90:6596-6600. 
Delfs J, Kong H, Mestek A, Chen Y, Yu L, Reisine T, Chesselet MF 
(1994) Expression of mu opioid receptor mRNA in rat brain. J Comp 
Neurol 345:46-68. 
Devereux J, Haeberli P, Smithies 0 (1984) A comprehensive set of 
sequence analysis programs for the VAX. Nucleic Acids Res 12:387- 
395. 
Di Chiara G, North RA (1992) Neurobiology of opiate abuse. Trends 
Pharmacol Sci 13:185-193. 
Dixon RA, Sigal IS, Strader CD (1988) Structure-function analysis of 
the P-adrenergic receptor. Cold Spring Harbor Symp Quant Biol 53: 
487-497. 
Doerner D, Pitler TA, Alger BE (1988) Protein kinase C activators 
block specific calcium and potassium current components in isolated 
hippocampal neurons. J Neurosci 8:40694078. 
Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ (1991) Model sys- 
tems for the study of seven-transmemhrane-segment receptors. Annu 
Rev Biochem 60:653-688. 
Evans CJ, Keith DEJ, Morrison H, Magendzo K, Edwards RH (1992) 
Cloning of a delta opioid receptor by functional expression. Science 
258:1952-1955. 
Fukuda K, Kato S, Mori K, Nishi M, Takeshima H (1993) Primary 
structures and expression from cDNAs of rat opioid receptor I% and 
p-subtypes. FEBS Lett 327:311-314. 
Guitart X, Nestler EJ (1993) Second messenger and protein phosphor- 
ylation mechanisms underlying opiate addiction: studies in the rat 
locus coeruleus. Neurochem Res 18:5-13. 
Gurdon JB, Wickens MP (1983) The use of Xenopus oocytes for the 
expression of cloned genes. Methods Enzymol 101:370-386. 
Harris GC, Williams JT (1991) Transient homologous FL-opioid recep- 
tor desensitization in rat locus coeruleus neurons. J Neurosci 11: 
2574-258 1. 
Johnson SM, Fleming WW (1989) Mechanisms of cellular adaptive 
sensitivity changes: applications to opioid tolerance and dependence. 
Pharmacol Rev 41:435488. 
Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG (1992) The 6-o- 
pioid receptor: isolation of a cDNA by expression cloning and phar- 
macological characterization. Proc Nat1 Acad Sci USA 89:12048- 
12052. 
Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY (1993) Primary 
structure and functional expression of a rat G-protein-coupled mus- 
carinic potassium channel. Nature 364:802-806. 
Lester J. Fink S. Aronin N. DiFiglia M (1993) Colocalization of D, 
and Dl dopamine recepto; mRNxs in striatal neurons. Brain Res 621 i 
106-l 10. 
Li S, Zhu J, Chen C, Chen YW, Deriel JK, Ashby B, Liu-Chen LY 
(1993) Molecular cloning and expression of a rat K opioid receptor. 
Biochem J 295:629-633. 
Loh HH, Tao PL, Smith AP (1988) Role of receptor regulation in 
opioid tolerance mechanisms. Synapse 2:457462. 
Louie AK, Bass ES, Zhan J, Law PY, Loh HH (1990) Attenuation of 
2406 Mestek et al. l Protein Kinases Modulate p Opioid Receptor Signaling 
opioid receptor activity by phorbol esters in neuroblastoma X glioma 
NG108-15 hybrid cells. J Pharmacol Exp Ther 253:401407. 
MacNicol M, Schulman H (1992) Multiple Caz+ signaling pathways 
converge on CaM kinase in PC12 cells: FEBS Lett 304:237-240. - 
Mansour A. Khachaturian H. Lewis ME. Akil H. Watson SJ (1987) 
Autoradiographic differentiation of mu, delta, and kappa opidid re: 
ceptors in the rat forebrain and midbrain. J Neurosci 7:2445-2464. 
Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) 
Anatomy of CNS opioid receptors. Trends Neurosci 11:308-314. 
Meng E Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ, 
Akil H (1993) Cloning and pharmacological characterization of a 
rat K opioid receptor. Proc Nat1 Acad Sci USA 90:995&9958. 
Minami &I, Toya Ti Katao Y, Maekawa K, Nakamura S, Onogi T, Ka- 
neko S. Satoh M (1993) Cloning. and exoression of a cDNA for the 
rat n-opioid receptor. FEBS Lett-329:291’-295. 
Munson PJ (1983) LIGAND: a computerized analysis of ligand binding 
data. Methods Enzymol 92:543-576. 
Nestler EJ, Hope BT, Widnell KL (1993) Drug addiction: a model for 
the molecular basis of neural plasticity. Neuron 11:995-1006. 
Neck B, Rajpara A, O’Connor LH, Cicero TJ (1988) Autoradiography 
of [SH]IJ-69593 binding sites in rat brain: evidence for kappa opioid 
receptor subtypes. Eur J Pharmacol 154:27-34. 
North RA (1986) Opioid receptor types and membrane ion channels. 
Trends Neurosci 9:114-l 17. 
North R (1993) Opioid actions on membrane ion channels. In: Hand- 
book of experimental pharmacology: opioids I, Vol 104 (Herz A, ed), 
pp 773-797. Berlin: Springer. 
North RA, Williams JT, Surprenant A, Christie MJ (1987) p and 6 
receptors belong to a family of receptors that are coupled to potas- 
sium channels. Proc Nat1 Acad Sci USA 84:5487-5491. 
Pastemak GW (1988) The opiate receptors. Totowa, NJ: Humana. 
Pasternak GW (1993) Pharmacological mechanisms of opioid analge- 
sics. Clin Neuropharmacol 16:1-18. 
Pfeiffer A, Pasi A, Mehraein P, Herz A (1982) Opiate receptor binding 
sites in human brain. Brain Res 248:87-96. 
Pilapil C, Welner S, Magnan J, Gauthier S, Quirion R (1987) Auto- 
radiographic distribution of multiple classes of opioid receptor bind- 
ing sites in human forebrain. Brain Res Bull 19:611-615. 
Porreca E Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of 
mu, delta and kappa opioid receptors in spinal and supraspinal me- 
diation of gastrointestinal transit effects and hot-plate analgesia in the 
mouse. J Pharmacol Exp Ther 230:341-348. 
Raynor K, Kong H, Yasuda K, Chen Y, Yu L, Bell GI, Reisine T (1994) 
Pharmacological characterization of the clones K, 6 and p opioid 
receptors. Mol Pharmacol 45:330-334. 
Schulman H (1984) Phosphorylation of microtubule-associated pro- 
teins by a Caz+/calmodulin-dependent protein kinase. J Cell Biol 99: 
11-19. 
Schulman H, Hanson PI (1993) Multifunctional Ca*+/calmodulin-de- 
pendent protein kinase. Neurochem Res 18:65-77. 
Tamaoki T (1991) Use and specificity of staurosporine, UCN-01, and 
calphostin C as protein kinase inhibitors. Methods Enzymol201:340- 
347. 
Thompson RC, Mansour A, Akil H, Watson SJ (1993) Cloning and 
pharmacological characterization of a rat p opioid receptor. Neuron 
11:903-913. 
Unterwald EM, Knapp C, Zukin RS (1991) Neuroanatomical localiza- 
tion of kappa 1 and kappa 2 opioid receptors in rat and guinea pig 
brain. Brain Res 562:57-65. 
Waldmann R, Hanson PI, Schulman H (1990) Multifunctional 
Ca*+/calmodulin-dependent protein kinase made Caz+-independent 
for functional studies. Biochemistry 29:1679-1684. 
Wang JB, Imai Y, Eppler CM, Gregor E Spivak CE, Uhl GR (1993) 
p Opiate receptor: cDNA cloning and expression. Proc Nat1 Acad 
Sci USA 90:10230-10234. 
Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR 
(1994) Human p opiate receptor: cDNA and genomic clones, phar- 
macologic characterization and chromosomal assignment. FEBS Lett 
338:217-222. 
Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic 
acetylcholine and dopamine receptor mRNAs in rat basal ganglia. 
Proc Nat1 Acad Sci USA 87:7050-7054. 
Williams JT, North RA, Tokimasa T (1988) Inward rectification of 
resting and opiate-activated potassium currents in rat locus coeruleus 
neurons. J Neurosci 8:4299-4306. 
Wimpey TL, Chavkin C (1991) Opioids activate both an inward rec- 
tifier and a novel voltage-gated potassium conductance in the hip- 
pocampal formation. Neuron 6:281-289. 
Wood PL (1988) The significance of multiple CNS opioid receptor 
types: a review of critical considerations relating to technical details 
and anatomy in the study of central opioid actions. Peptides 9:49- 
55. 
Wood PL, Ivengar S (1988) Central actions of ouiates and ooioid oeu- 
tides: ii i&evidence for opioid receptor multiplicity. In: The opiate 
receotors (Pasternak GW. ed). DD 307-356. Clifton. NJ: Humana. 
Yaksh &TL (198 1) Spinal opiate analgesia: characteristics and principles 
of action. Pain 11:293-346. 
Yanagihara N, Tachikawa E, Izumi E Yasugawa S, Yamamoto H, Mi- 
yamoto E (1991) Staurosporine: an effective inhibitor for 
Ca*+/calmodulin-deuendent protein kinase II. J Neurochem 56:29& 
298. 
Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell 
GI (1993) Cloning and functional comparison of K and 6 opioid 
receptors from mouse brain. Proc Nat1 Acad Sci USA 90:6736-6740. 
